

B1  
December 21, 1989 in the United Kingdom, the entire content of each of said applications is incorporated by reference herein.--

Amend the above-identified specification in accordance with the enclosed copy of a preliminary amendment (dated 7/8/92) filed in applicants' Serial No. 07/743,329 application which enters the Sequence Listing as replacement pages 67-89, and rennumbers original pages 67-70 as pages 90-93, respectively, and amends the specification to refer to said listing appropriately.

In the claims:

Cancel claim 1 without prejudice and enter the following claims 24-31 in this application:

Sub H1  
B2  
--24. A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains, which humanized immunoglobulin specifically binds to an antigen with an affinity constant of at least  $10^8 \text{ M}^{-1}$ , wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside both the Kabat CDRs and the structural loop CDRs of the variable regions, wherein the donor amino acids replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks, and each of said donor amino acids is adjacent to a CDR in the donor immunoglobulin sequence.

25. A humanized immunoglobulin according to claim 24 which specifically binds to an antigen with an affinity in the range  $10^8$ - $10^{12}$  M<sup>-1</sup>.

26. A humanized immunoglobulin according to claim 24, wherein the antigen is an IL-2 receptor.

B2  
27. A humanized immunoglobulin according to claim 24, wherein the donor immunoglobulin is the anti-CD4 T-cell receptor antibody.

08846558-050197  
Sub 42  
28. A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains, which humanized immunoglobulin specifically binds to an antigen with an effective antigen binding affinity, wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside both the Kabat CDRs and the structural loop CDRs of the variable regions, wherein the donor amino acids replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks, and each of said donor amino acids is adjacent to a CDR in the donor immunoglobulin sequence.

Sub 13 29. A humanized immunoglobulin according to claim 28 which specifically binds to an antigen with a binding affinity equivalent to that of a chimeric antibody formed from said donor immunoglobulin.

B2 30. A humanized immunoglobulin according to claim 28, wherein the antigen is a human CD3 T-cell receptor.

31. A humanized immunoglobulin according to claim 28, wherein the donor immunoglobulin is the anti-CD3 T-cell receptor antibody.--

---

#### REMARKS

Applicants have entered claims 24-31 to request an interference in accordance with 37 CFR §1.607 as follows. It is noted that the Queen patent whose claims present the basis for an interference is classified in Class 424/133.1. MPEP §2306 suggests a transfer to the group where the patent is classified.

#### Compliance With 37 CFR §1.607(a)

##### (a) Identification of the Patent

Applicants request that an interference be declared between applicants' above-identified application and Queen et al., U.S. Patent No. 5,585,089 (hereinafter "the Queen patent"), issued December 17, 1996, a copy of which is enclosed herewith. Applicants have in claims 24-27 substantially copied claims 1, 5,